韩国对2型糖尿病中OAD三重治疗的安全性和有效性的研究 (TRIO)
一项多中心,前瞻性,非差异观察研究,以评估OAD三重治疗在韩国2型糖尿病患者中的安全性和有效性
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
研究概览
详细说明
The study was designed as a multicenter, prospective, non-interventional, observational study in patients with type 2 diabetes mellitus who had inadequate glycemic control with conventional combination oral hypoglycemic agents including metformin.
Participants in this study will have type 2 diabetes mellitus with insufficient glycemic control on conventional combination therapy with a DPP-4i or SGLT2i oral hypoglycemic agent, including metformin, requiring the addition of one of the following: SGLT-2i, DPP-4i, or TZD.
The 3-drug combination therapy will be prescribed to subjects based on the medical judgment of the investigator based on the licensure of SGLT-2i, DPP-4i, or TZD(efficacy, dosing, precautions for use, etc.) in a real-world practice setting and all treatment and observation, including administration of medications and laboratory tests, will be based on the medical judgment of the investigator.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Soo Lim, M.D, Ph.D.
- 电话号码:82-2-6373-0773
- 邮箱:limsoo@snu.ac.kr
学习地点
-
-
Gyeonggi-do
-
Seongnam-si、Gyeonggi-do、韩国
- 招聘中
- Seoul National University Bundang Hospital
-
接触:
- Soo Lim, M.D, Ph.D.
- 电话号码:1588-3369
- 邮箱:limsoo@snu.ac.kr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with type 2 diabetes mellitus whose glycemic control is inadequate on 2 oral hypoglycemic agents, including metformin.
描述
Inclusion Criteria:
- Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.
- Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.
- 7.0% ≤ HbA1c < 10.0% based on laboratory tests performed within 4 weeks of enrollment.
- Voluntarily give written informed consent after being told about the study.
Exclusion Criteria:
- Patients with type 1 diabetes and secondary diabetes.
- Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.
- Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.
- End-stage renal disease and hemodialysis patients.
- diabetic ketoacidosis Patients.
- Pregnant and lactating women.
- Patients who are contraindicated by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice.
- Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients.
- Anyone else deemed by the investigator to be unsuitable for participation in the study.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Metformin/DPP4i/SGLT2i
Metformin + DPP4i 2-drug combination plus one of the SGLT-2i class of drugs. |
SGLT2 inhibitor class of drugs DPP4 inhibitor class of drugs |
|
Metformin/DPP4i/TZD
Metformin + DPP4i 2-drug combination plus one of the TZD class of drugs. |
DPP4 inhibitor class of drugs Thiazolidinedione class of drugs |
|
Metformin/SGLT2i/DPP4i
Metformin + SGLT2i 2-drug combination plus one of the DPP4i class of drugs. |
SGLT2 inhibitor class of drugs DPP4 inhibitor class of drugs |
|
Metformin/SGLT2i/TZD
Metformin + SGLT2i 2-drug combination plus one of the TZD class of drugs. |
SGLT2 inhibitor class of drugs Thiazolidinedione class of drugs |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety Evaluation of Triple Combination Therapy with SGLT-2i, DPP-4i, or TZD Class Drugs, Including Metformin
大体时间:Up to 24 months
|
Safety will be assessed based on all adverse events, laboratory test results, and vital signs collected after enrollment during the study period. |
Up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in HbA1c
大体时间:3, 6, (9), 12, 18, and 24 months
|
Evaluation of HbA1c(%) Change Compared to Baseline in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Changes in FPG
大体时间:3, 6, (9), 12, 18, and 24 months
|
Evaluation of FPG(mg/dL) Change Compared to Baseline in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Percentage of Subjects with HbA1c < 7.0%
大体时间:3, 6, (9), 12, 18, and 24 months
|
Percentage of Subjects with HbA1c < 7.0% in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Percentage of Subjects with HbA1c < 6.5%
大体时间:3, 6, (9), 12, 18, and 24 months
|
Percentage of Subjects with HbA1c < 6.5% in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Factors influencing HbA1c change at each time point in each combination group.
大体时间:3, 6, (9), 12, 18, and 24 months
|
demographics, previous hypoglycemic medications, hypoglycemic medication components and doses, duration of hypoglycemic medication, duration of disease, comorbidities, concomitant medications, etc. |
3, 6, (9), 12, 18, and 24 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in Weight
大体时间:3, 6, (9), 12, 18, 24 months
|
Changes in Weight(kg) Compared to Baseline in Each Combination Group |
3, 6, (9), 12, 18, 24 months
|
|
Changes in waist circumference
大体时间:12 and 24 months
|
Changes in waist circumference(cm) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Changes in body composition(protein mass)
大体时间:12 and 24 months
|
Change in total protein mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in body composition(protein mass)
大体时间:12 and 24 months
|
Change in protein mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in body composition(body fat)
大体时间:12 and 24 months
|
Change in body fat mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in body composition(mineral mass)
大体时间:12 and 24 months
|
Change in mineral mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in Fatty Liver Index
大体时间:6, 12, 18, and 24 months
|
Changes in Fatty Liver Index compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in AST
大体时间:6, 12, 18, and 24 months
|
Changes in AST(IU/L) Compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in ALT
大体时间:6, 12, 18, and 24 months
|
Changes in ALT(IU/L) Compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes Platelet Levels
大体时间:6, 12, 18, and 24 months
|
Changes in Platelet(10^3/uL) Levels Compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in Blood Lipid Levels(Total cholesterol, LDL-C, HDL-C, TG)
大体时间:6, 12, 18, and 24 months
|
Change in Total cholesterol, LDL-C, HDL-C, TG(mg/dL) compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in Insulin-Related Test Levels(HOMA-IR)
大体时间:12 and 24 months
|
Changes in HOMA-IR compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Changes in Insulin-Related Test Levels(HOMA-β)
大体时间:12 and 24 months
|
Changes in HOMA-β(%) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Changes in eGFR
大体时间:6, 12, 18, and 24 months
|
Changes in eGFR(mL/min/1.73m2) compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in UACR
大体时间:6, 12, 18, and 24 months
|
Changes in UACR(mg/g) compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Change in hsCRP
大体时间:12 and 24 months
|
Change in hsCRP(mg/dL) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Change in ProBNP(or NT-ProBNP)
大体时间:12 and 24 months
|
Change in ProBNP(or NT-ProBNP)(pg/mL) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Change in PP2 Compared to Baseline in Each Combination Group
大体时间:3, 6, (9), 12, 18, and 24 months
|
Change in PP2(mg/dL) compared to Baseline in Each Combination Group. |
3, 6, (9), 12, 18, and 24 months
|
|
Incidence Rate of Major Adverse Cardiovascular Events(MACE)
大体时间:24 month
|
Incidence Rate of Major Adverse Cardiovascular Events(MACE) from Baseline to 24 Months for Each Combination Group |
24 month
|
|
Incidence Rate of Diabetic Microvascular Events
大体时间:24 month
|
Incidence Rate of Diabetic Microvascular Events from Baseline to 24 Months for Each Combination Group |
24 month
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.